ALG3-CDG: a patient with novel variants and review of the genetic and ophthalmic findings

[1]  J. Rosenfeld,et al.  Expanding the phenotype, genotype and biochemical knowledge of ALG3‐CDG , 2021, Journal of inherited metabolic disease.

[2]  E. Morava,et al.  Fetal glycosylation defect due to ALG3 and GOG5 variants detected via amniocentesis: Complex glycosylation defect with embryonic lethal phenotype. , 2020, Molecular genetics and metabolism.

[3]  C. Qiao,et al.  ALG3-CDG: lethal phenotype and novel variants in Chinese siblings , 2020, Journal of Human Genetics.

[4]  R. Horvath,et al.  Successful treatment of intractable epilepsy with ketogenic diet therapy in twins with ALG3-CDG , 2020, Brain and Development.

[5]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[6]  A. Ziegler,et al.  Novel variants and clinical symptoms in four new ALG3‐CDG patients, review of the literature, and identification of AAGRP‐ALG3 as a novel ALG3 variant with alanine and glycine‐rich N‐terminus , 2019, Human mutation.

[7]  Gregory M. Cooper,et al.  CADD: predicting the deleteriousness of variants throughout the human genome , 2018, Nucleic Acids Res..

[8]  F. Alkuraya,et al.  Congenital disorders of glycosylation: The Saudi experience , 2017, American journal of medical genetics. Part A.

[9]  K. Stehlikova,et al.  Muscular dystrophies and myopathies: the spectrum of mutated genes in the Czech Republic , 2017, Clinical genetics.

[10]  Gill Bejerano,et al.  M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity , 2016, Nature Genetics.

[11]  C. Barba,et al.  Congenital disorders of glycosylation presenting as epileptic encephalopathy with migrating partial seizures in infancy , 2016, Developmental medicine and child neurology.

[12]  G. Matthijs,et al.  ALG3‐CDG: Report of two siblings with antenatal features carrying homozygous p.Gly96Arg mutation , 2015, American journal of medical genetics. Part A.

[13]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[14]  Jana Marie Schwarz,et al.  MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.

[15]  G. Matthijs,et al.  ALG3-CDG (CDG-Id): clinical, biochemical and molecular findings in two siblings. , 2013, Molecular genetics and metabolism.

[16]  T. Hennet.  Diseases of glycosylation beyond classical congenital disorders of glycosylation. , 2012, Biochimica et biophysica acta.

[17]  Jing Hu,et al.  SIFT web server: predicting effects of amino acid substitutions on proteins , 2012, Nucleic Acids Res..

[18]  Machiko Kadoya,et al.  Transferrin mutations at the glycosylation site complicate diagnosis of congenital disorders of glycosylation type I , 2011, Journal of Inherited Metabolic Disease.

[19]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[20]  A. Superti-Furga,et al.  Congenital disorder of glycosylation type Id (CDG Id): phenotypic, biochemical and molecular characterization of a new patient , 2008, Journal of Inherited Metabolic Disease.

[21]  H. Freeze,et al.  CDG‐Id in two siblings with partially different phenotypes , 2007, American journal of medical genetics. Part A.

[22]  J. Denecke,et al.  Congenital Disorder of Glycosylation Type Id: Clinical Phenotype, Molecular Analysis, Prenatal Diagnosis, and Glycosylation of Fetal Proteins , 2005, Pediatric Research.

[23]  W. Chung,et al.  Congenital disorder of glycosylation id presenting with hyperinsulinemic hypoglycemia and islet cell hyperplasia. , 2005, The Journal of clinical endocrinology and metabolism.

[24]  G. Matthijs,et al.  CDG-Id caused by homozygosity for an ALG3 mutation due to segmental maternal isodisomy UPD3(q21.3-qter). , 2005, European journal of medical genetics.

[25]  J. Denecke,et al.  An activated 5′ cryptic splice site in the human ALG3 gene generates a premature termination codon insensitive to nonsense‐mediated mRNA decay in a new case of congenital disorder of glycosylation type Id (CDG‐Id) , 2004, Human mutation.

[26]  U. Stephani,et al.  Carbohydrate deficient glycoprotein syndrome type IV: deficiency of dolichyl‐P‐Man:Man5 GlcNAc2‐PP‐dolichyl mannosyltransferase , 1999, The EMBO journal.

[27]  P. Striano,et al.  Electroclinical Features of Early-Onset Epileptic Encephalopathies in Congenital Disorders of Glycosylation (CDGs). , 2016, JIMD reports.

[28]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..